Showing results (281-290 of 368) with videos related to

Sort By:
Pageof 37
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Circulation|October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
American Heart Journal|May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVERAnkeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
European Journal of Heart Failure|May 21, 2023
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HFSafia Chatur, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection FractionSara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
European Heart Journal|August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillationToru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
Circulation|August 26, 2023
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER TrialSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 37